Joseph L Kuti

Summary

Affiliation: Hartford Hospital
Country: USA

Publications

  1. ncbi request reprint Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital
    Edward M Grant
    Ortho McNeil Pharmaceutical, Inc, Raritan, New Jersey, USA
    Pharmacotherapy 22:471-83. 2002
  2. ncbi request reprint The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion
    Srividya Kotapati
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT, USA
    Intensive Crit Care Nurs 21:87-93. 2005
  3. ncbi request reprint Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem
    Anthony M Nicasio
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Ann Pharmacother 41:1077-81. 2007
  4. ncbi request reprint Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Pharmacotherapy 24:1641-5. 2004
  5. doi request reprint Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Semin Respir Crit Care Med 30:102-15. 2009
  6. ncbi request reprint Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital
    Joseph L Kuti
    Clinical and Economic Studies, Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Conn Med 73:337-40. 2009
  7. doi request reprint Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia
    Anthony M Nicasio
    Center for AntiInfective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    J Crit Care 25:69-77. 2010
  8. ncbi request reprint Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study
    Su Young Lee
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Infect Control Hosp Epidemiol 27:1226-32. 2006
  9. ncbi request reprint Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Pharmacotherapy 27:333-42. 2007
  10. ncbi request reprint Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program
    Christine T Ong
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Surg Infect (Larchmt) 6:419-26. 2005

Collaborators

Detail Information

Publications96

  1. ncbi request reprint Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital
    Edward M Grant
    Ortho McNeil Pharmaceutical, Inc, Raritan, New Jersey, USA
    Pharmacotherapy 22:471-83. 2002
    ..To compare continuous versus intermittent administration of piperacillin-tazobactam with regard to clinical, microbiologic, and economic outcomes...
  2. ncbi request reprint The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion
    Srividya Kotapati
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT, USA
    Intensive Crit Care Nurs 21:87-93. 2005
    ..Additionally, advantages related to a reduction in nursing resource consumption will be a focus of discussion...
  3. ncbi request reprint Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem
    Anthony M Nicasio
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Ann Pharmacother 41:1077-81. 2007
    ..To describe the use of and cerebral spinal fluid (CSF) penetration of a prolonged infusion meropenem regimen in a patient with Serratia marcescens meningitis...
  4. ncbi request reprint Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Pharmacotherapy 24:1641-5. 2004
    ..This case demonstrates that pharmacodynamic principles can be used to design an antibiotic dosing regimen that can achieve optimal exposures when the MIC is above that considered susceptible to conventional dosing strategies...
  5. doi request reprint Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Semin Respir Crit Care Med 30:102-15. 2009
    ..Finally, continued feedback of program results is critical to maintaining compliance as well as for reevaluating empirical antibiotic choices...
  6. ncbi request reprint Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital
    Joseph L Kuti
    Clinical and Economic Studies, Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Conn Med 73:337-40. 2009
    ..None of the isolates tested were positive for hVISA; four isolates were VISA. Vancomycin MICs for respiratory MRSA at this Connecticut hospital are elevated. Institution-specific surveillance in the state is warranted...
  7. doi request reprint Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia
    Anthony M Nicasio
    Center for AntiInfective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    J Crit Care 25:69-77. 2010
    ....
  8. ncbi request reprint Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study
    Su Young Lee
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Infect Control Hosp Epidemiol 27:1226-32. 2006
    ..To evaluate the economic and clinical impact of infection with extended-spectrum beta -lactamase (ESBL)-producing Escherichia coli and Klebsiella species (ESBL-EK)...
  9. ncbi request reprint Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Pharmacotherapy 27:333-42. 2007
    ..To determine the likelihood that antibiotic regimens achieve bactericidal pharmacodynamic exposures against common nosocomial pathogens...
  10. ncbi request reprint Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program
    Christine T Ong
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Surg Infect (Larchmt) 6:419-26. 2005
    ..By simulating the probability of achieving target bactericidal exposures, the pharmacodynamics of three beta-lactam agents were compared against a range of pathogens implicated commonly in complicated skin and soft tissue infections...
  11. doi request reprint Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia
    Anthony M Nicasio
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Pharmacotherapy 30:453-62. 2010
    ....
  12. ncbi request reprint Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program
    Heather K Sun
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT, USA
    Crit Care Med 33:2222-7. 2005
    ..To compare the probability of achieving specific pharmacodynamic exposures of commonly used intravenous antibiotics for the empirical treatment of nosocomial pneumonia against those pathogens most commonly implicated in the disease...
  13. ncbi request reprint Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Drugs 66:1-14. 2006
    ..Future work is needed to fully characterise these target concentrations that prevent resistance...
  14. doi request reprint Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa
    Kathryn J Eagye
    Center for Anti Infective Research and Development, Hartford Hospital, CT 06102, USA
    Infect Control Hosp Epidemiol 30:746-52. 2009
    ..To determine risk factors and outcomes for patients with meropenem high-level-resistant Pseudomonas aeruginosa (MRPA) (minimum inhibitory concentration [MIC] > or = 32 microg/mL)...
  15. doi request reprint In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals
    Kathryn J Eagye
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Clin Ther 31:2678-88. 2009
    ..Current surveillance data are informative, but may not discern differences by infection site and clinical setting, and do not incorporate pharmacodynamic (PD) characteristics when determining susceptibility...
  16. ncbi request reprint Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Aryun Kim
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Pharmacotherapy 27:1490-7. 2007
    ..To compare conventional intermittent dosing regimens of piperacillin-tazobactam with prolonged and continuous infusions to determine the optimal dosing scheme against a local Pseudomonas aeruginosa population...
  17. doi request reprint Surgical site infections: does inadequate antibiotic therapy affect patient outcomes?
    Kathryn J Eagye
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Surg Infect (Larchmt) 10:323-31. 2009
    ..This study assessed the impact of IAT on primary outcomes of length of stay (LOS) and costs in complicated SSIs; identifying risk factors associated with receiving IAT was a secondary objective...
  18. doi request reprint Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia
    Aryun Kim
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Clin Ther 31:2765-78. 2009
    ..The pharmacodynamic characteristics of antibiotics should be considered when choosing empiric dosage regimens for the treatment of pneumonia...
  19. ncbi request reprint Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program
    Srividya Kotapati
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Surg Infect (Larchmt) 6:297-304. 2005
    ..375 g q6h and 4.5 g q8h in the empiric treatment of secondary peritonitis...
  20. ncbi request reprint Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections
    Su Young Lee
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    J Infect 54:463-8. 2007
    ..This study was designed to compare cefepime exposures with microbiological outcomes in ESBL and non-ESBL infections and determine the pharmacodynamic profiles associated with successful outcome...
  21. pmc Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers
    Seth T Housman
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA
    Antimicrob Agents Chemother 56:2627-34. 2012
    ..0. The mean ELF penetration ratio after population analyses was 39.7. This study demonstrates that tedizolid penetrates into ELF and AM to levels approximately 40-fold and 20-fold, respectively, higher than free-drug exposures in plasma...
  22. doi request reprint The current state of multidrug-resistant gram-negative bacilli in North America
    Anthony M Nicasio
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT, USA
    Pharmacotherapy 28:235-49. 2008
    ....
  23. ncbi request reprint Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Pharmacotherapy 25:935-41. 2005
    ..To compare the pharmacodynamics of two beta-lactams--ceftazidime and meropenem--in healthy subjects versus patients...
  24. doi request reprint Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program
    Pornpan Koomanachai
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Int J Antimicrob Agents 33:348-53. 2009
    ..aeruginosa and A. baumannii...
  25. pmc Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods
    Catharine C Bulik
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    J Clin Microbiol 48:2402-6. 2010
    ..Meropenem MIC results and categorical interpretations for carbapenemase-producing K. pneumoniae differ by methodology. Confirmation of testing results is encouraged when an accurate MIC is required for antibiotic dosing optimization...
  26. doi request reprint Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections
    Somvadee Laohavaleeson
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Pharmacotherapy 28:1471-82. 2008
    ..To determine the cost-effectiveness of telavancin versus vancomycin for the treatment of complicated skin and skin structure infections (cSSSIs)...
  27. doi request reprint Optimization of meropenem dosage in the critically ill population based on renal function
    Jared L Crandon
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT, 06102, USA
    Intensive Care Med 37:632-8. 2011
    ..To develop a meropenem population pharmacokinetic model in critically ill patients with particular focus on optimizing dosing regimens based on renal function...
  28. ncbi request reprint Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients
    Chonghua Li
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    J Clin Pharmacol 46:1171-8. 2006
    ..5, 1, 2, and 3 hours. The 3-hour prolonged infusion improved the likelihood of obtaining both bacteriostatic and bactericidal exposures most notably at the current susceptibility breakpoints...
  29. pmc Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia
    Anthony M Nicasio
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 53:1476-81. 2009
    ..8%, 78.1%, and 50.3% for MICs of 8, 16, and 32 microg/ml, respectively. This study provides a pharmacokinetic model capable of predicting cefepime concentrations in critically ill patients with VAP...
  30. ncbi request reprint Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation
    Kathryn J Eagye
    Center for Anti In fective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Clin Ther 29:889-99. 2007
    ..The selection of an appropriate agent can be challenging because of the emerging resistance of target organisms to commonly prescribed antibiotics...
  31. pmc Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 50:3529-34. 2006
    ..The results of this study suggest that the addition of gentamicin does not alter the pharmacokinetic profile or enhance the bactericidal activity of daptomycin against staphylococcal or enterococcal isolates...
  32. pmc Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults
    Jared L Crandon
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 53:5102-7. 2009
    ..In healthy adult volunteers, voriconazole achieved high levels of exposure in both ELF and AM, while anidulafungin predominantly concentrated in AM...
  33. pmc Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa
    Jared L Crandon
    Center for Anti Infective Research and Development, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 54:1111-6. 2010
    ..In patients with non-urinary tract infections caused by P. aeruginosa, achievement of cefepime exposures of >60% fT > MIC will minimize the possibility of a poor microbiological response...
  34. ncbi request reprint Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling
    Kathryn J Eagye
    Center for Anti Infective Research Development, Hartford Hospital, Hartford, CT 06102, USA
    Surg Infect (Larchmt) 8:215-26. 2007
    ....
  35. doi request reprint Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Surg Infect (Larchmt) 9:57-66. 2008
    ....
  36. ncbi request reprint Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Diagn Microbiol Infect Dis 58:337-44. 2007
    ....
  37. ncbi request reprint Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06112, USA
    J Clin Pharmacol 43:1116-23. 2003
    ..Further study of these dosage recommendations in clinical trials is suggested...
  38. ncbi request reprint Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Connecticut 06102, USA
    Pharmacotherapy 24:8-15. 2004
    ..To compare the pharmacodynamics of meropenem and imipenem, both administered as 500 mg every 6 hours, against populations of Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa...
  39. ncbi request reprint Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts
    Srividya Kotapati
    Clinical and Economic Studies, Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102 5037, USA
    Am J Health Syst Pharm 61:1264-70. 2004
    ..The clinical and economic outcomes of a meropenem dosage strategy based on pharmacodynamic concepts are retrospectively reviewed...
  40. doi request reprint Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States
    Aryun Kim
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Mycoses 54:e301-12. 2011
    ..Only initial treatment with intravenous voriconazole was associated with reduced total hospitalisation costs...
  41. ncbi request reprint Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection
    Chonghua Li
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    J Antimicrob Chemother 56:388-95. 2005
    ..We investigated the population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam in hospitalized patients...
  42. ncbi request reprint Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study
    Naomi R Florea
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102 5037, USA
    Am J Health Syst Pharm 60:2321-7. 2003
    ..The use of continuous infusion as a means of administering piperacillin-tazobactam maximized the drug's pharmacodynamics and was more cost-efficient than intermittent infusion of the drug...
  43. pmc In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase
    Dora E Wiskirchen
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 55:1420-7. 2011
    ..837). The combination of tigecycline with high-dose, prolonged-infusion meropenem warrants further study as a potential treatment option for these multidrug-resistant organisms...
  44. doi request reprint Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures
    Kirthana Raman
    Department of Pharmacy, Hartford Hospital, Hartford, CT, USA
    Crit Care Med 41:1656-63. 2013
    ....
  45. pmc In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus
    Mao Hagihara
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA
    Antimicrob Agents Chemother 56:202-7. 2012
    ....
  46. doi request reprint Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa
    Mao Hagihara
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Diagn Microbiol Infect Dis 72:258-62. 2012
    ..However, meropenem and imipenem nonsusceptible isolates should be directly tested against doripenem since the latter antibiotic may still retain susceptibility against these isolates...
  47. pmc Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis
    Dora E Wiskirchen
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 55:4170-5. 2011
    ..42; range, 1.08 to 2.23) and wound (1.27; range, 0.86 to 2.26) tissues (P = 0.648). With the currently approved dosing regimen, linezolid penetrated well into both healthy thigh tissue and infected wound tissue in these diabetic patients...
  48. ncbi request reprint Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients
    Xiaoli Du
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    J Clin Pharmacol 46:69-75. 2006
    ..The microbiological outcomes indicate that the current clinical dosage regimen provides sufficient drug exposure to eradicate the pathogens commonly involved in pediatric meningitis...
  49. doi request reprint Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia
    Kathryn J Eagye
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Semin Respir Crit Care Med 30:116-23. 2009
    ..001], with 15.6 days and $48,527 attributable to superinfection. While not affecting mortality in those patients with VAP, superinfections independently predict increased LOS after VAP ID, contributing to substantial additional cost...
  50. pmc Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis
    Rebecca A Keel
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Antimicrob Agents Chemother 55:3393-8. 2011
    ..Standard i.v. and oral dosing regimens should be sufficient to reliably attain pharmacodynamic targets against most MRSA isolates; however, more frequent dosing may be required for isolates with MICs of ≥ 2 μg/ml...
  51. doi request reprint Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance
    Jared L Crandon
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Ann Pharmacother 43:220-7. 2009
    ..Resistance among gram-negative bacteria is increasing within the US...
  52. ncbi request reprint Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Clin Ther 26:493-501. 2004
    ....
  53. ncbi request reprint Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Am J Health Syst Pharm 63:750-5. 2006
  54. doi request reprint Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies
    Rebecca A Keel
    Center for Anti Infective Research and Development, Hartford, CT 06102, USA
    Diagn Microbiol Infect Dis 68:326-9. 2010
    ..Etest and BMD identified a significant, albeit poor, correlation between MICs (ρ = 0.29, P < .01, and ρ = 0.15, P = .01, respectively), but no correlation (ρ = 0.08, P = .18) was observed with MicroScan...
  55. pmc Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model
    Catharine C Bulik
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 54:804-10. 2010
    ..Thus, predicting the efficacy of an antimicrobial regimen based on MIC may not be a valid assumption for KPC-producing organisms...
  56. ncbi request reprint Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness
    Srividya Kotapati
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102 5037, USA
    J Infect 51:211-7. 2005
    ..To determine the affect of ESBL production among Klebsiella species and Escherichia coli on cefepime effectiveness...
  57. doi request reprint Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics
    Anthony M Nicasio
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    J Med Microbiol 57:1147-51. 2008
    ....
  58. ncbi request reprint Making the most of surveillance studies: summary of the OPTAMA Program
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Diagn Microbiol Infect Dis 53:281-7. 2005
    ..Collectively, the approach of the OPTAMA Program provides a novel tool that complements susceptibility data to help in the selection of appropriate empirical antibiotic therapy at the national, regional, and institutional level...
  59. doi request reprint Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers
    Dora E Wiskirchen
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Pharmacotherapy 33:266-74. 2013
    ..To compare ertapenem pharmacokinetics, pharmacodynamics, and tolerability when administered as a rapid 5-minute infusion to the standard 30-minute infusion...
  60. ncbi request reprint Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy
    Pornpan Koomanachai
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Conn, USA
    Undersea Hyperb Med 38:11-6. 2011
    ..We describe linezolid tissue penetration in two diabetic patients with lower-extremity ulcers, measured by in vivo microdialysis, before and after hyperbaric oxygen (HBO2) therapy...
  61. doi request reprint Pharmacodynamic evaluation of i.v. antimicrobials against Pseudomonas aeruginosa samples collected from U.S. hospitals
    Rebecca A Keel
    Center for Anti Infective Research and Development, Hartford Hospital, CT 06102, USA
    Am J Health Syst Pharm 68:1619-25. 2011
    ..Selected i.v. antimicrobials were evaluated against Pseudomonas aeruginosa isolates collected from U.S. hospitals to predict the likelihood of achieving maximal bactericidal activity...
  62. doi request reprint Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States
    Pornpan Koomanachai
    Center for Anti effective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Clin Ther 32:766-79. 2010
    ..In an attempt to improve antimicrobial selection, pharmacodynamic modeling that considers the drug, dose, dosing interval, and duration of infusion is increasingly used as a tool to assist in the clinical decision-making process...
  63. pmc Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis
    Catharine C Bulik
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 54:5209-13. 2010
    ..Tissue penetration ratios (tissue fAUC/plasma fAUC) were 99% in the thigh and 100% in the wound (P = 0.964). Tigecycline penetrated equally well into wound and uninfected tissue of the same extremity...
  64. doi request reprint Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population
    Joshua D Courter
    Connecticut Children s Medical Center, Hartford, Connecticut, USA
    Pediatr Blood Cancer 53:379-85. 2009
    ..As children exhibit increased drug clearance, this may further the benefit of prolonged or continuous infusions. This dosing approach was applied to several beta-lactams commonly utilized in children...
  65. ncbi request reprint Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Conn Med 69:271-5. 2005
  66. pmc Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour St, P O Box 5037, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 48:2464-70. 2004
    ....
  67. ncbi request reprint Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae
    Heather K Sun
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Chest 130:807-14. 2006
    ..To determine if penicillin-nonsusceptible Streptococcus pneumoniae, among other variables, was significantly associated with greater hospital costs among patients with community-acquired pneumonia (CAP)...
  68. ncbi request reprint Review of dalbavancin, a novel semisynthetic lipoglycopeptide
    Aryun Kim
    Center for Anti Infective Research and Development, Connecticut, USA
    Expert Opin Investig Drugs 16:717-33. 2007
    ..Dalbavancin may serve as an appealing alternative agent in the treatment of gram-positive infections, especially with its convenient once-weekly regimen...
  69. pmc Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections
    Chonghua Li
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA
    Antimicrob Agents Chemother 51:1725-30. 2007
    ..The findings for LRTI patients can be applied to optimize meropenem dose regimens to achieve clinical success and microbiological eradication in clinical practice...
  70. ncbi request reprint Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102 5037, USA
    Am J Health Syst Pharm 60:565-8. 2003
    ..A pharmacodynamically influenced dosage strategy for meropenem resulted in %t > MIC exposure similar to standard regimens and required a lesser amount of the drug, thereby reducing costs without compromising efficacy...
  71. pmc In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers
    Aryun Kim
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Antimicrob Agents Chemother 52:3941-6. 2008
    ..Moreover, these free, bioactive concentrations in tissue exceeded the MICs for staphylococci and streptococci over the 24-h dosing interval...
  72. ncbi request reprint Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program
    Dana Maglio
    Center for Anti Infective Research and Development, Hartford Hospital, CT 06102, USA
    Clin Ther 27:1032-42. 2005
    ....
  73. ncbi request reprint Polymyxins: older antibiotics for a new threat
    Su Young Lee
    Center for Anti Infective Research and Development, Hartford Hospital, USA
    Conn Med 70:25-8. 2006
    ..Pharmacodynamic studies are still needed to determine appropriate dosage regimens that will optimize effectiveness and minimize toxicity...
  74. ncbi request reprint Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Int J Antimicrob Agents 28:62-8. 2006
    ..7% to 4.2%), whilst bacteriostatic CFRs overestimated actual CR and MR. This study demonstrates that the use of Monte Carlo simulation to predict the CR of meropenem in complicated skin and skin structures is accurate...
  75. ncbi request reprint Update on daptomycin: the first approved lipopeptide antibiotic
    Su Young Lee
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Expert Opin Pharmacother 7:1381-97. 2006
    ....
  76. ncbi request reprint Role of pharmacodynamics in designing dosage regimens for beta-lactams
    Srividya Kotapati
    Center for Anti Infective Research and Development, Hartford Hospital, USA
    Conn Med 67:265-8. 2003
  77. ncbi request reprint Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, CT 06102 5037, USA
    Chemotherapy 51:211-6. 2005
    ..We employed Monte Carlo simulation to calculate the bactericidal target attainment for various dosing regimens of meropenem against Pseudomonas aeruginosa and Acinetobacter species...
  78. ncbi request reprint Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis
    Joseph L Kuti
    Department of Pharmacy Research, Hartford Hospital, Hartford, CT, USA
    Diagn Microbiol Infect Dis 44:51-7. 2002
    ..aeruginosa infections due to the higher established breakpoint, these data suggest a high probability of achieving adequate drug exposure against susceptible isolates with this dosing regimen...
  79. ncbi request reprint Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance
    Joseph L Kuti
    Department of Pharmacy Research, Hartford Hospital, Connecticut 06102, USA
    Pharmacoeconomics 20:513-28. 2002
    ..These pathways should be specific to each institution, thus considering the resistance rates in the area and encouraging the use of the most active, cost-effective agents to produce rapid, positive clinical outcomes...
  80. ncbi request reprint Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem
    Holly M Mattoes
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Clin Ther 26:1187-98. 2004
    ..Consideration of pharmacodynamic principles in dosage regimens for these agents can maximize their antibacterial effectiveness and reduce the number of bacterial strains that survive to mutate or continue infection...
  81. ncbi request reprint Treatment of Clostridium difficile-associated disease (CDAD)
    Naomi R Florea
    Department of Pharmacy Research, Hartford Hospital, USA
    Conn Med 67:153-5. 2003
  82. ncbi request reprint Emerging Pseudomonas aeruginosa resistance: implications in clinical practice
    Christine T Ong
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, USA
    Conn Med 68:11-5. 2004
  83. ncbi request reprint Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections
    Joseph L Kuti
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Pharmacoeconomics 22:301-10. 2004
    ..Potential differences in toxicity, potency and acquisition price among the liposomal amphotericin B formulations makes it unclear which agent is less costly when total resource consumption and treatment-associated costs are considered...
  84. ncbi request reprint Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals
    Endre Ludwig
    Szent László Hospital, Department of Clinical Microbiology and Infectiology, Budapest, Hungary
    Int J Antimicrob Agents 28:433-8. 2006
    ..aeruginosa in Hungary...
  85. ncbi request reprint When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection
    Effie L Gillespie
    University of Connecticut, School of Pharmacy, Storrs, USA
    Conn Med 69:203-10. 2005
    ..Initial therapy should have a high likelihood of covering resistant pathogens...
  86. ncbi request reprint A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit
    Carlos R V Kiffer
    Microbiology Section, Fleury Institute, Avenida General Waldomiro de Lima 508, 04344 070 Jabaquara, Sao Paulo, SP, Brazil
    Braz J Infect Dis 11:183-5. 2007
    ....
  87. ncbi request reprint Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral
    Joseph L Kuti
    Department of Pharmacy Research, Hartford Hospital HH, Hartford, CT, USA
    Am J Health Syst Pharm 59:2209-15. 2002
    ..v. to p.o. without physician approval reduced length of stay and institutional health care costs without compromising clinical outcomes...
  88. ncbi request reprint Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children
    Renee M Fallon
    Department of Pharmacy Services, Maine Medical Center, Portland, Maine, USA
    Paediatr Drugs 10:329-35. 2008
    ..To determine the probability of oral beta-lactam regimens achieving bactericidal pharmacodynamic exposure against pathogens causing acute otitis media (AOM) given contemporary prevalence and resistance rates...
  89. pmc Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection
    William K Lau
    The Queens Medical Center, 1301 Punchbowl Street, Honolulu, HI 96813, USA
    Antimicrob Agents Chemother 50:3556-61. 2006
    ..The results of this study support continuous infusion as a safe and reasonable alternate mode of administration of piperacillin-tazobactam for the treatment of complicated intra-abdominal infection...
  90. ncbi request reprint Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil
    Carlos R V Kiffer
    Fleury Institute, Sao Paulo, Brazil
    Int J Antimicrob Agents 28:340-4. 2006
    ..05). Against E. coli, CFRs were close to 100%. Ertapenem is probably an effective agent against ESBL-producing bacteria, although its ability to achieve bactericidal pharmacodynamic exposures will depend on the bacterial susceptibility...
  91. ncbi request reprint Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance
    Su Young Lee
    Center for Anti Infective Research and Development, Hartford Hospital, Hartford, Connecticut 06102, USA
    Surg Infect (Larchmt) 6:283-95. 2005
    ....
  92. ncbi request reprint Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004
    Hui Wang
    Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
    Int J Antimicrob Agents 30:452-7. 2007
    ..90% CFR against A. baumannii and P. aeruginosa. Pharmacodynamic analyses are useful for selecting optimal compounds and dosing regimens as initial empirical therapy against these organisms in China...
  93. ncbi request reprint Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program
    Jennifer M Ellis
    Department of Pharmacy Practice, University of Connecticut, School of Pharmacy, Storrs, USA
    Paediatr Drugs 8:131-8. 2006
    ..Bridgewater, NJ, USA) achieving bactericidal exposures in the cerebrospinal fluid against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae...
  94. ncbi request reprint Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002
    Carlos R V Kiffer
    Fleury Medical Diagnostic Center and University of São Paulo, Sao Paulo, Brazil
    Diagn Microbiol Infect Dis 49:109-16. 2004
    ..Because of the lack of agreement with percent susceptibility for certain antimicrobial regimens, the use of pharmacodynamic target attainment may be a more accurate predictor of microbiologic success...
  95. ncbi request reprint The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe
    Robert G Masterton
    Ayrshire and Arran Acute Hospitals Trust, Crosshouse Hospital, Kilmarnock, Ayrshire, UK
    J Antimicrob Chemother 55:71-7. 2005
    ....
  96. ncbi request reprint Telavancin: a novel lipoglycopeptide for serious gram-positive infections
    Somvadee Laohavaleeson
    Hartford Hospital, Center for Anti Infective Research and Development, 80 Seymour Street, Hartford, CT 06102, USA
    Expert Opin Investig Drugs 16:347-57. 2007
    ..aureus, vancomycin-resistant S. aureus and vancomycin-resistant enterococci...